Esperion Therapeutics, Inc. (ESPR) Analysis

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] Esperion Therapeutics Inc (ESPR) 3-Minute Overview > **💡 One-Sentence Summary** > > Simply put, Esperion is a small commercial-stage biotech focused on cholesterol-lowering drugs, and right now the story is less about long-term upside and more about the company being bought out at roughly today’s price. > **📍 Basic Profile** > > Market Cap **$0.80 billion** · Pharmaceuticals · NASDAQ NMS - GLOBAL MARKET · Price **$3.11** > **⚡ 3 Things You Should Know** > > 1. 💰 Business is no longer just a “hope stock”: Esperion has commercial revenue, strong gross margin at **67.95%**, and **3-year revenue growth of 74.78%**—so the core product demand looks real, not purely trial-stage speculation. > > 2. ⚠️ Profit quality is still uneven: even with a positive operating margin (**14.95%**), trailing net margin is still **-5.63%** and cash flow per share is negative, which basically means the business has improved a lot but hasn’t fully become a clean, self-funding pharma model yet. > > 3. 🎯 The market is now pricing the deal, not the dream: news says **ARCHIMED will acquire Esperion for $3.16/share in cash plus milestone rights**, and the stock at **$3.11** is already very close to that level—so upside from here likely depends more on deal completion and milestone value than on standalone execution. > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |-----------|--------|---------| > | Profitability | Medium✋ | Net margin **-5.63%**, gross margin strong but bottom line still slightly negative | > | Growth Rate | Fast🚀 | 3-year revenue growth **74.78%** | > | Financial Health | Moderate💛 | Current ratio **1.54**, but negative cash flow and weak interest coverage | > | Valuation | Fair | PE **[Data unavailable]**, PS **1.99x**; takeover price anchors valuation | --- ## 📋 Layer 2: 2-Minute Deep Dive #### 📊 How Does This Company Make Money? **Business Model in One Sentence:** Esperion sells prescription cardiometabolic therapies—primarily cholesterol-lowering drugs—to the healthcare market, making money through product sales and related commercialization activity. **Revenue Breakdown:** | Business | Share | Trend | Comment | |----------|-------|-------|---------| | Cholesterol-lowering therapies / core commercial products | [Data unavailable] | ↑ | Main value driver; recent guideline inclusion supports demand | | Other / partnership-related revenue | [Data unavailable] | → | Likely supplementary, but no detailed segment split provided | **Profitability Metrics:** | Metric | Value | Ranking | Interpretation | |--------|-------|---------|----------------| | Gross Margin | 67.95% | Above Average | Strong for a small biotech; suggests its products can generate attractive economics | | Net Margin | -5.63% | Below Average | Close to breakeven, but still not consistently profitable at the bottom line | | ROE | -59.48% | Below Average | Very weak on paper, likely distorted by accumulated losses and small equity base | --- #### 📈 How's the Growth? **Growth Assessment:** High Growth | Metric | Latest | vs Last Year | Trend | |--------|--------|--------------|-------| | Revenue Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Quality:** > What’s interesting is that the growth story looks more credible than many small biotech names because Esperion is already commercial-stage, not purely pre-revenue. The recent news flow also helps: its bempedoic acid was added to major U.S. heart health guidelines, which can support prescribing momentum. That said, the latest Q4 report was described as mixed, with revenue and EPS both missing some expectations, so growth is real but not perfectly smooth. --- #### 💰 Financial Health Check **One Sentence:** Think of it like a company that has enough cash to keep the lights on for now, but it’s not financially bulletproof and still depends on execution staying on track. | Metric | Value | Safe Zone | Assessment | |--------|-------|-----------|------------| | Debt Ratio | 0% debt-to-equity | <60% safe | ✅Safe | | Current Ratio | 1.54 | >1.5 healthy | ✅Safe | | Cash Flow | Negative (cash flow/share **-2.23**) | >0 | ⚠️Volatile | Worth noting: debt-to-equity shows as zero, which looks good on the surface, but interest coverage is only **0.743**, so the full liability picture may be more complicated than that headline ratio suggests. In other words, this is not a balance sheet you’d call rock-solid. --- #### 🏷️ Is It Expensive Now? **Price Position (based on 52-week range):** - 52-Week Low: **$0.69** - 52-Week High: **$4.18** - Current: **$3.11**, **in the pricey end of the range** | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|------------|-----------|-------------| | Criteria | 0-33% | 33-66% | 66-100% | | **Current** | | | ●(**69.4%** position) | **Valuation Comparison:** | Comparison | Current | Reference | Assessment | |------------|---------|-----------|------------| | vs Own History | PE **[Data unavailable]** | 5-year avg **[Data unavailable]** | [Data unavailable] | | vs Peers | PS **1.99x** | Industry avg **[Data unavailable]** | [Data unavailable] | **What the Current Valuation is Betting On:** > Basically, the current valuation is no longer mainly betting on Esperion’s independent future. It’s betting that the **$3.16/share cash acquisition** closes as expected, plus some optional value from the milestone payments. That’s why the stock trading near **$3.11** leaves limited obvious upside unless the milestone rights are worth more than the market currently assumes. --- #### 📰 Any Recent News? | Date | Event | Impact | |------|-------|--------| | 2026-05-01 | Esperion to be acquired by ARCHIMED for **$3.16/share in cash** plus milestone rights up to **$100M** | Positive + takeover creates a valuation floor, but also caps near-term upside | | 2026-05-01 | HC Wainwright downgraded ESPR to Neutral with **$3.16** target | Neutral/Negative + confirms Wall Street now sees the stock as a deal-arbitrage situation | | 2026-03-14 | Bempedoic acid added to major U.S. heart health guidelines | Positive + strengthens product legitimacy and could support prescribing trends | | 2026-03-10 | Q4 2025 results mixed; sales and EPS missed estimates | Neutral + business progress continues, but execution still isn’t perfectly clean | --- ## 📊 Layer 3: Want More? 3-Minute Complete Analysis #### I. Detailed Financial Data **Profitability Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Gross Margin | 67.95% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Net Margin | -5.63% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | ROE | -59.48% | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Revenue Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | ↑ | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | EPS Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | --- #### II. Earnings Track Record **Last 4 Quarters vs Expectations:** | Quarter | EPS Expected | EPS Actual | Surprise | |---------|--------------|------------|----------| | 2025-12-31 | $0.25 | $0.22 | -10.46% Miss 😟 | | 2025-09-30 | -$0.06 | -$0.16 | -183.69% Miss 😟 | | 2025-06-30 | -$0.15 | -$0.02 | +86.51% Beat 😀 | | 2025-03-31 | -$0.16 | -$0.21 | -33.00% Miss 😟 | **Earnings Trend Interpretation:** Esperion’s earnings record is choppy, not steadily improving. One strong beat in mid-2025 shows the model can surprise on the upside, but three misses in the last four quarters tell you forecasting the business is still tricky—which is pretty common for smaller biopharma names with uneven commercialization timing. --- #### III. What the Market Thinks **Analyst Ratings:** | Rating | Count | Percentage | |--------|-------|------------| | Strong Buy/Buy | 11 firms | 78.6% | | Hold | 2 firms | 14.3% | | Sell | 1 firm | 7.1% | **Target Price:** $3.16 ~ $5.00 (known from provided news flow; full range **[Data unavailable]**) **vs Current Price:** roughly **1.6% upside to $3.16 cash deal price**, with additional upside only if milestone rights are valued more highly **Insider Activity:** Net mixed, but recent filings show both award-related additions and subsequent sales in March 2026 > On balance, this doesn’t read like a strong insider conviction signal. The “A” transactions look like grants/awards, while the “S” transactions show some actual selling shortly after. That’s not automatically bearish, but it also isn’t the kind of heavy open-market buying that screams management thinks the stock is deeply undervalued. --- #### IV. Key Risk Alerts **3 Risks to Watch:** 1. **Deal Risk:** The current stock price is tied closely to the acquisition terms → If the deal is delayed, repriced, or falls apart, the stock could drop sharply because takeover premium would unwind. 2. **Commercial Execution Risk:** Revenue momentum depends on continued uptake of its cholesterol therapies → If prescribing growth slows, standalone valuation support gets weaker fast. 3. **Cash Flow / Earnings Volatility:** Negative cash flow and inconsistent earnings surprises show the business still has uneven financial quality → If costs rise or sales disappoint, profitability could slip back meaningfully. --- ## 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** Esperion is a small commercial biotech built around cholesterol-lowering therapies, and the stock now trades more like a merger situation than a pure growth story. > > **Key strength:** The big positive is that this is a real revenue-generating drug business with strong gross margins and improving commercial relevance, helped by recent guideline inclusion. > > **Key risk:** The main concern is that most of the near-term value appears already pinned to the **$3.16** buyout price, so if the deal doesn’t close smoothly, downside could reopen quickly. --- > **🔍 Want to Learn More?** > > • Want to know if this company has a strong moat? → Try【Buffett Mode】for deeper analysis > > • Want to check for hidden landmines? → Try【Muddy Mode】for risk screening > > • Is this a growth stock? Want to calculate if it's worth the bet? → Try【Musk Mode】for analysis